Howe & Rusling’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Howe & Rusling’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20	Closed	-$2K	–	903
2019 Q4	$2K	Buy	+20	New	+$1.79K	﹤0.01%	709
2016 Q3	–	Sell	-3	Closed	–	–	1142
2016 Q2	$0	Hold	3	–	–	﹤0.01%	1067
2016 Q1	$0	Hold	3	–	–	﹤0.01%	1071
2015 Q4	$0	Hold	3	–	–	﹤0.01%	1087
2015 Q3	$0	Hold	3	–	–	﹤0.01%	1085
2015 Q2	$1K	Buy	+3	New	+$799	﹤0.01%	991

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Howe & Rusling's ICPT Position: Q1 2020 in Review

Howe & Rusling sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 20 shares — an estimated $2K sold.

Howe & Rusling first reported a position in ICPT in Q2 2015 and held it in 6 quarters. The position peaked at $2K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

Howe & Rusling reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Howe & Rusling sold 20 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $2K.
Howe & Rusling first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2015 and held it in 6 quarters.
Howe & Rusling's Intercept Pharmaceuticals, Inc. position peaked at $2K in Q4 2019.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.